Dual Orexin Receptor Antagonists (DORAs) for Insomnia
A newer class of insomnia medication is offering hope to those struggling with sleep. Known as dual orexin receptor antagonists (DORAs), these drugs work differently from traditional sleep aids by targeting brain chemicals that keep people awake. Three DORAs have now been approved by the FDA, providing patients with fresh options for managing their condition.
DORAs function by blocking orexins, natural chemicals in the brain that promote wakefulness. Unlike other sleep medications, which often act as sedatives, DORAs specifically disrupt the signals that prevent rest. Research shows they help users fall asleep faster, stay asleep longer, and improve overall sleep quality.
The first DORA, suvorexant (sold as Belsomra), gained FDA approval in August 2014. Two more followed: lemborexant (Dayvigo) in 2019 and daridorexant (Quviviq) in 2022. Lemborexant is produced by Eisai Co., Ltd., a Japanese pharmaceutical company. Clinical trials highlight several advantages of DORAs over older sleep drugs. They do not appear to cause tolerance, withdrawal symptoms, or rebound insomnia when discontinued. However, some users report side effects like daytime drowsiness, headaches, dizziness, or nausea. For people wary of habit-forming medications, DORAs may present a safer alternative. Their unique mechanism makes them a distinct choice in the treatment of insomnia.
With three FDA-approved options now available, DORAs provide a science-backed approach to tackling insomnia. Their ability to improve sleep without the risks of dependency or severe withdrawal could make them a preferred choice for many. Doctors and patients alike now have an expanded range of treatments to consider.
%20for%20Insomnia){kind=link}